Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 1;131(7):e35814.
doi: 10.1002/cncr.35814.

Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network study

Alexandre Bertucci  1   2 , Ondine Dufour  2 , Romain Appay  1   3 , Vincent Harlay  2 , François Ducray  4 , Charlotte Bronnimann  5 , Apolline Djelad  6 , Elisabeth Cohen-Jonathan Moyal  7 , Mario Campone  8 , Olivier Langlois  9 , Mathilde Ducloie  10 , Elodie Vauleon  11 , Nadia Younan  12 , Christine Desenclos  13 , Carole Ramirez  14 , Mehdi Touat  15 , Ahmed Idbaih  15 , Céline Bequet  2   16 , Dominique Figarella-Branger  1   16 , Caroline Dehais  15 , Olivier Chinot  1   2 , Emeline Tabouret  1   2   16 ; POLA network
Affiliations

Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network study

Alexandre Bertucci et al. Cancer. .

Abstract

Background: Brain tumors represent one of the main causes of cancer-related mortality in young patients. Among them, oligodendrogliomas (OG) are adult-type diffuse gliomas with the best prognosis. Nevertheless, characterization of these tumors in the young population remains poorly documented. Our objective was to characterize the population of young adults under 40 years of age with grade 3 OG in the POLA cohort.

Methods: Clinical data prospectively collected for all patients registered with grade 3 OG between April 2009 and August 2021 were extracted from the national POLA database. This study compared the patient subgroup <40 years of age to the one >40 years of age.

Results: The authors included 111 patients <40 years old and 363 patients ≥40 years old. Treatment received did not differ significantly between the two subgroups. Temporal location was more frequent in older patients (p = .009). Patients <40 years old presented more often seizure as initial symptom (p = .003). They had less frequent chromosome 9p loss (p < .001) and less CDKN2A homozygous deletion (p = .024). Median progression-free survival (PFS) was 123 months (range, 86-not reached [NR]) versus 88 months (range, 67-117) (p = .082) and median overall survival (OS) was not reached (range, 147-NR) versus 163 months (range, 137-NR) (p < .001) in younger and older subgroups, respectively. In multivariate analysis, complete or subtotal resection (p = .014) and seizure at diagnosis (p = .032) were associated with better OS.

Conclusion: Young patients with grade 3 OG have distinct clinical presentation, molecular features, and outcomes compared to the older patients.

Keywords: glioma; grade 3 oligodendroglioma; molecular features; prognostic factors; young patient.

PubMed Disclaimer

Conflict of interest statement

Mathilde Ducloie reports grant and/or contract funding from Novocure and Servier Azaires Medicales; and travel funding from Kyowa Hakko Kirin and Servier Pharmaceuticals LLC. Francois Ducray reports fees for professional activities from Novocure Israel Ltd; and consulting fees from Novocure Israel Ltd and Servier Azaires Medicales. Ondine Dufour reports travel funding from Roche. Ahmed Idbaih reports consulting fees from Boehringer Ingelheim, Leo Pharma, Novartis, Novocure, and Polytone Laser; grant and/or contract funding from Nutritheragene, Servier Pharmaceuticals LLC, and Transgene; and travel funding from Carthera, Leo Pharma, and Novocure Inc. Olivier Langlois reports fees for professional activities from Kyowa Kirin Pharmaceutical Development, Inc; and consulting fees from Seagen Inc and Servier Pharmaceuticals LLC. Emeline Tabouret reports consulting fees from Servier Pharmaceuticals LLC. Mehdi Touat reports consulting fees from NH Theraguix, Novocure, Ono Pharmaceuticals, and Servier Pharmaceuticals LLC. Elodie Vauleon reports fees for professional activities from Novocure and Servier Pharmaceuticals LLC. The other authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Distribution of tumor locations in (A) young adults <40 years old and (B) older patients ≥40 years old. Mann‐Whitney U test for frontal lobe (p = .076), temporal lobe (p = .009), parietal lobe (p = .114), occipital lobe (p = .133), corpus callosum (p = .392), and insular lobe (p = .136).
FIGURE 2
FIGURE 2
Impact of young age (<40 years) versus older age on clinical (A) and molecular (B) characteristics. Chrom indicates chromosome.
FIGURE 3
FIGURE 3
Progression‐free survival (A) and overall survival (B) of patients according to their age subgroups.
See this image and copyright information in PMC

References

    1. Kuo CW, Chen YM, Tsai CM, Perng RP, Chao JY. Non‐small cell lung cancer in very young and very old patients. Chest. 2000;117(2):354‐357. doi:10.1378/chest.117.2.354 - DOI - PubMed
    1. Dufour O, Houvenaeghel G, Classe JM, et al. Early breast cancer in women aged 35 years or younger: a large national multicenter French population‐based case control‐matched analysis. Breast. 2023;68:163‐172. doi:10.1016/j.breast.2023.02.004 - DOI - PMC - PubMed
    1. Papageorgiou GI, Razis ED. CNS tumors in adolescents and young adults: the need for a holistic specialized approach. JCO Oncol Pract. 2020;16(4):155‐162. doi:10.1200/JOP.18.00767 - DOI - PubMed
    1. Lim‐Fat MJ, Cotter JA, Touat M, et al. A comparative analysis of IDH‐mutant glioma in pediatric, young adult, and older adult patients. Neuro Oncol. 2024;26(12):noae142. doi:10.1093/neuonc/noae142 - DOI - PMC - PubMed
    1. Lim‐Fat MJ, Bennett J, Ostrom Q, et al. Central nervous system tumors in adolescents and young adults: a Society for Neuro‐Oncology consensus review on diagnosis, management, and future directions. Neuro Oncol. 2024;23(1):noae186. doi:10.1093/neuonc/noae186 - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources